Found 1298 clinical trials
Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors (TusaRav-QT)
participants with metastatic colorectal cancer (CRC), nonsquamous non small cell lung cancer (NSQ NSCLC), or gastric/ gastroesophageal junction (GEJ) adenocarcinoma for which in the judgement of the
- 0 views
- 07 Mar, 2023
- 4 locations
A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (202200050434)
Study 849-017 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of combination therapies with adagrasib in patients with advanced NSCLC with TPS ā„ 1% and KRAS G12C mutation
- 38 views
- 20 Dec, 2022
- 24 locations
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304) (POD1UM-304)
cell lung cancer (NSCLC).
- 25 views
- 19 Dec, 2022
- 120 locations
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
- 0 views
- 28 Oct, 2022
- 13 locations
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as monotherapy or in combination with INCMGA00012 in participants with selected CD8 T-cell-positive advanced solid tumors including SCCHN, NSCLC, ovarian cancer, CRPC, TNBC, bladder ā¦
- 54 views
- 11 Jul, 2022
- 19 locations
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03)
progression free survival (PFS) when compared to docetaxel in participants with metastatic non-squamous non-small-cell lung cancer (NSCLC) expressing CEACAM5 greater than or equal to 2+ in intensity in at
- 181 views
- 17 Feb, 2023
- 5 locations
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced Non-Small Cell Lung Cancer With an FGFR Alteration Who Progressed on Previous Therapy (FIGHT 210) (FIGHT-210)
This is an open-label, single arm study to study the safety, efficacy and tolerability of Pemigatinib when used on participants with squamous or nonsquamous NSCLC with a documented FGFR1-3 mutations or fusions/rearrangement who have progressed on prior therapies and have no available standard treatment options
- 0 views
- 28 Oct, 2022
- 17 locations
Small cell lung cancer (SCLC) Receiving Zepzelca
People with SMALL CELL LUNG CANCER are asked to participate in a research study being conducted by Montefiore Medical Center.
- 3 views
- 06 Aug, 2021
- 1 location
Non-Small Cell Lung Cancer Research Study from Home
At Sanguine, we are accelerating medicine with the help of volunteers like you. You can contribute to the development of new treatments and help advance Non-Small Cell Lung Cancer research with
- 0 views
- 01 Dec, 2022
- 1 location
EF-36/Keynote: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer
-3475) in subjects previously untreated for their advance or metastatic intrathoracic, PD-L1 positive (TPSā„1% [tumor proportion score]) non-small cell lung cancer (NSCLC).
- 0 views
- 29 Nov, 2022
- 1 location